On August 2, public hearings were held to discuss the draft mark-up of the Single Distributor as a subject of special rights to medicines and medical devices within the framework of the guaranteed volume of free medical care and the compulsory medical insurance system.
As part of the implementation of the Entrepreneurial Code, by order of the Agency for the Protection and Development of Competition of the Republic of Kazakhstan, the state register of subjects of state monopoly, special law was approved and published on the official website of the Agency. The Single Distributor, which carries out its activities in the state regulated market, is also referred to the subjects of special law.
The list, marginal selling prices and markups are established by the authorized body.
In accordance with the legislation, subjects of special law are required to keep separate records of income, costs and involved assets for each type of activity, including technologically related types of activity.
In turn, the antimonopoly authority conducts an examination of prices for goods produced and sold by the state monopoly entity, special right in accordance with the Rules for Pricing Goods, Works, Services. The corresponding order No. 134 “On approval of the Rules for pricing goods, works, services produced and sold by a state monopoly entity, special law” was approved by the Minister of National Economy of the Republic of Kazakhstan dated March 15, 2016.
Public hearings are one of the mandatory procedures for approving the cost of services provided by a subject of special law. Conducting public hearings to discuss the draft margin shows the transparency and openness of the activities of the Single Distributor.
The discussion was attended by representatives of the antimonopoly authority represented by the Agency for the Protection and Development of Competition of the Republic of Kazakhstan, as well as representatives of the Ministry of Health of the Republic of Kazakhstan, the NGO "Kazakhstan Association of Health Managers", the Public Council of the Ministry of Health of the Republic of Kazakhstan, the National Chamber of Entrepreneurs of the Republic of Kazakhstan "Atameken", the ALE "Association of Pharmaceutical Manufacturers and medical products PharmMedIndustry of Kazakhstan, NGO "Eurasian Medical Association", NGO "Union of Public Education and Independent Expertise in Medicine" and the media.
The draft mark-up under consideration is based on actual costs at the end of 2022. The largest expenses fall on logistics services - transportation, storage and loading and unloading of medicines and medical devices, which account for 45% of the costs associated with the sale of medicines by the Single Distributor.
Timeliness and continuity of drug supply is the main strategic task. It is of particular concern in the context of exceptional situations that lead to a significant increase in demand for certain medicines, following the experience of the COVID-19 pandemic.
Delivery of medicines and medical devices to medical organizations is carried out regardless of their distance or from any circumstances all year round. Many of the medical facilities are located in remote, hard-to-reach areas. But even in the most distant villages and in any bad weather, medicines are delivered strictly according to the schedule.
In addition, in order to prevent interruptions in the country's drug supply, it is planned to form an irreducible supply of medicines at the expense of the Single Distributor's own funds. Which, in turn, will allow - uninterrupted drug supply, mitigation of the risks of incorrect planning, prompt response to the needs of medical supply in case of emergency.
Another factor in the increase in markup is the cost-effectiveness of the single distribution system, which serves as an indicator of economic efficiency.
Based on the results of the public hearings, the documents with the draft order of the Ministry of Health of the Republic of Kazakhstan on the size of the margin will be sent to the Agency for the Protection and Development of Competition of the Republic of Kazakhstan.
Источник: Пресс-служба ТОО "СК-Фармация"
